WO2008109757A3 - Procédés et compositions mettant en œuvre des protéines hybrides d'immunoglobuline polymériques - Google Patents

Procédés et compositions mettant en œuvre des protéines hybrides d'immunoglobuline polymériques Download PDF

Info

Publication number
WO2008109757A3
WO2008109757A3 PCT/US2008/056066 US2008056066W WO2008109757A3 WO 2008109757 A3 WO2008109757 A3 WO 2008109757A3 US 2008056066 W US2008056066 W US 2008056066W WO 2008109757 A3 WO2008109757 A3 WO 2008109757A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
fusion proteins
immunoglobulin fusion
compositions involving
polymeric immunoglobulin
Prior art date
Application number
PCT/US2008/056066
Other languages
English (en)
Other versions
WO2008109757A2 (fr
Inventor
Barry G Arnason
Mark A Jensen
David M White
Original Assignee
Iterative Therapeutics Inc
Barry G Arnason
Mark A Jensen
David M White
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iterative Therapeutics Inc, Barry G Arnason, Mark A Jensen, David M White filed Critical Iterative Therapeutics Inc
Priority to CA002679743A priority Critical patent/CA2679743A1/fr
Priority to EP08731555A priority patent/EP2164859A4/fr
Publication of WO2008109757A2 publication Critical patent/WO2008109757A2/fr
Publication of WO2008109757A3 publication Critical patent/WO2008109757A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne de nouveaux polypeptides. La présente invention concerne également des compositions et des vaccins comportant les polypeptides selon l'invention. Selon d'autres modes de réalisation, les polypeptides selon l'invention sont administrés à un sujet, utilisés pour vacciner, ou utilisés pour induire l'immunité. D'autres modes de réalisation concernent des procédés de fabrication des polypeptides selon l'invention et d'acides nucléiques utilisés pour coder pour les polypeptides selon l'invention.
PCT/US2008/056066 2007-03-06 2008-03-06 Procédés et compositions mettant en œuvre des protéines hybrides d'immunoglobuline polymériques WO2008109757A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002679743A CA2679743A1 (fr) 2007-03-06 2008-03-06 Procedes et compositions mettant en oeuvre des proteines hybrides d'immumoglobuline polymeriques
EP08731555A EP2164859A4 (fr) 2007-03-06 2008-03-06 Procédés et compositions mettant en oeuvre des protéines hybrides d'immunoglobuline polymériques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89331807P 2007-03-06 2007-03-06
US60/893,318 2007-03-06

Publications (2)

Publication Number Publication Date
WO2008109757A2 WO2008109757A2 (fr) 2008-09-12
WO2008109757A3 true WO2008109757A3 (fr) 2008-12-24

Family

ID=39739113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/056066 WO2008109757A2 (fr) 2007-03-06 2008-03-06 Procédés et compositions mettant en œuvre des protéines hybrides d'immunoglobuline polymériques

Country Status (3)

Country Link
EP (1) EP2164859A4 (fr)
CA (1) CA2679743A1 (fr)
WO (1) WO2008109757A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2536465T3 (es) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
WO2013095973A1 (fr) 2011-12-19 2013-06-27 The Rockefeller University Peptides de liaison à hdc-sign
WO2017096221A1 (fr) * 2015-12-02 2017-06-08 The Rockefeller University Anticorps largement neutralisants anti-vih bispécifiques
JP7368007B2 (ja) * 2018-07-24 2023-10-24 グッド ティー セルズ、 インコーポレイテッド 免疫関連疾患の予防または治療用組成物
WO2020110154A1 (fr) * 2018-11-30 2020-06-04 Bharat Biotech International Limited Vaccin thérapeutique chimérique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072608A2 (fr) * 2001-03-09 2002-09-19 University Of Chicago Proteines hybrides d'immunoglobulines polymeriques ciblant des recepteurs fc$g(g) a faible affinite

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DUAN ET AL.: "Antitumor activities of TEM8-Fc: an engineered antibody-like molecule targeting tumor endothelial marker 8", J. NATL. CANCER INST., vol. 99, no. 20, 17 October 2007 (2007-10-17), pages 1551 - 1555, XP008126478 *
HEIJNEN ET AL.: "Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice", J OPIN INVEST., vol. 97, no. 2, 15 January 1996 (1996-01-15), pages 331 - 338, XP002345168 *
JENSEN ET AL.: "A novel Fc gamma receptor ligand augments humoral responses by targeting antigen to Fc gamma receptors", EUR. J. IMMUNOL., vol. 37, no. 4, April 2007 (2007-04-01), pages 1139 - 1148, XP008126476 *
WERNERSSON ET AL.: "IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice", J. IMMUNOL., vol. 163, no. 2, 15 July 1999 (1999-07-15), pages 618 - 622, XP008126477 *
WHITE ET AL.: "Design and expression of polymeric immunoglobulin fusion proteins: a strategy for targeting low-affinity Fcgamma receptors", PROTEIN EXPR. PURIF., vol. 3, 21 April 2001 (2001-04-21), pages 446 - 455, XP008126475 *

Also Published As

Publication number Publication date
EP2164859A2 (fr) 2010-03-24
CA2679743A1 (fr) 2008-09-12
WO2008109757A2 (fr) 2008-09-12
EP2164859A4 (fr) 2012-06-06

Similar Documents

Publication Publication Date Title
WO2011008974A3 (fr) Compositions à base de protéine f du vrs et procédés de fabrication associés
IL195191A (en) Digested Proteins, Nucleic Acids Encoded, and the Process of Creating
WO2008114149A3 (fr) Antigènes chimériques
EP2037737A4 (fr) Protéines, acides nucléiques encodant celles-ci et leurs procédés d'utilisation associés
IL200808A0 (en) Soluble il-17ra/rc fusion proteins and related methods
WO2010120514A3 (fr) Protéines liant des antigènes comprenant des échafaudages protéiniques internes recombinants
WO2008145401A3 (fr) Protéines structurales de parvovirus mutées en tant que vaccins
IL198592A (en) Proteins linked to 4ig – b7h3, nucleic acids encode it, and methods for creating and using it
IL218296A0 (en) Obpgplys/endolysin polypeptides, fusion proteins and compositions compriisng the same and uses thereof
IL210485A (en) An isolated antibody or its functional protein, a process for making it, a pharmaceutical preparation containing it, and an isolated amino acid encoding an antibody or a functional protein
IL223989B (en) Albumin binding polypeptide, fusion protein or conjugate comprising said polypeptide, polynucleotide encoding said albumin binding polypeptide and various aspects related thereto
WO2007133835A3 (fr) Mutation de ras et compositions et méthodes associées
MX300732B (es) Celulasas, acidos nucleicos que las codifican y metodos para hacerlas y usarlas.
WO2008143679A9 (fr) Acides nucléiques et protéines et procédés pour leur fabrication et leur utilisation
EP1892547A4 (fr) Dispositif de renfort par chauffage, dispositif de raccordement par fusion comprenant le dispositif de renfort par chauffage et procédé de raccordement par fusion
WO2007042289A3 (fr) Nanobodies™ et polypeptides diriges contre l'egfr et l'igf-1r
ZA201405521B (en) Plant co2 sensors,nucleic acids encoding them ,and methods for making and using them
EP2089053A4 (fr) Compositions vaccinales a base de proteine de fusion de l'antigene hpv et utilisations de celles-ci
WO2007095350A3 (fr) Compositions et procedes utilisant des fragments de peptide du facteur derive d'epithelium pigmentaire (pedf)
EP1934372A4 (fr) Proteines hybrides ssb-polymerase
WO2008083271A3 (fr) Procédés et compositions pour l'expression et la purification de protéines améliorées
EP2237794A4 (fr) Protéines hybrides vih chimèriques utilisées en tant que vaccins
PT2144924T (pt) Vacina de proteína de fusão
IL169804A (en) 254p1d6b proteins, nucleic acids encoding the same, processes for producing the same, antibodies binding thereto and uses thereof
WO2008109757A3 (fr) Procédés et compositions mettant en œuvre des protéines hybrides d'immunoglobuline polymériques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731555

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2679743

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008731555

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE